Introduction
Prion protein (PrP) is a glycoprotein that is synthesized through the secretory pathway and accumulates as a glycosyl phosphatidylinositol (GPI) anchored-protein at the cell surface (Caughey et al., 1989) . In addition, PrP is retrotranslocated from the endoplasmic reticulum to the cytosol as cytosolic PrP (CyPrP) (Zanusso et al., 1999; Ma and Lindquist, 2001; Yedidia et al., 2001; Roucou et al., 2003) . PrP is highly expressed in brain, and its sequence is well conserved among mammalian species (Kretzschmar et al., 1986; Wopfner et al., 1999) , indicating an important function for the normal cellular PrP. PrP promotes cell survival (for review, see Roucou et al., 2004) . Neuronal PrP knock-out cells are more susceptible to apoptosis than PrPexpressing cells (Kuwahara et al., 1999) . PrP prevents tumor necrosis factor-␣-induced cell death in the breast carcinoma MCF-7 cells (Diarra-Mehrpour et al., 2004) . In primary cultures of human neurons and in MCF-7 cells, PrP prevents the Bax conformational change involved as the first step of Bax activation into a proapoptotic protein and subsequently Bax-mediated mitochondrial cytochrome c release and cell death (Bounhar et al., 2001; Roucou et al., 2003 . Furthermore, PrP is able to overcome Bax-mediated cell death in yeast cells (Bounhar et al., 2006) . Because Bax is a strong inducer of neuronal apoptosis (White et al., 1998) , this could be a very important function for PrP.
Disease-specific mutations of the PrP gene (PRNP) correspond to 10 -15% of human transmissible spongiform encephalopathies. More than 30 dominant single point mutations and insertions have been identified in PRNP; 11 single point mutations confer Creutzfeldt-Jacob disease (CJD) (Windl et al., 1999; Gambetti et al., 2003) . In addition to the pathogenic mutations in PRNP, a polymorphism at codon 129 encodes either a methionine (Met 129 ) or a valine (Val 129 ). The codon 129 polymorphism affects the susceptibility to prion diseases, the phenotype of CJD, and dictates the manifestation of either CJD or fatal familial insomnia (FFI) associated with the D178N PrP mutation (Goldfarb et al., 1992; Wadsworth et al., 2004) .
Because neuronal apoptosis occurs in CJD and FFI patients (Dorandeu et al., 1998; Gray et al., 1999; Kawashima et al., 2001; Ferrer, 2002) , here we investigate the anti-Bax function of both the Met 129 and Val 129 alleles of 11 PrP CJD mutations, one FFI mutation, and one Gerstmann-Straussler-Scheinker disease (GSS) mutation. We show that all familial PrP mutations tested decrease or abolish the anti-Bax function in primary human neurons and, except for A117V and V203I, in MCF-7 cells. The loss of anti-Bax function in these PrP mutants correlates completely with a significant decrease in the production of CyPrP, a form of PrP shown previously to have anti-Bax function in human neu-into the BamH I and HindIII sites of the pCep4␤ vector to generate pCep4␤-CyPrP or pCep4␤-CyPrP GPI.
Analysis of the PrP polymorphism at codon 129
The Met/Val 129 polymorphism of PrP in MCF-7 cells and human neurons was detected by PCR amplification with the upstream 5Ј-GGAA-CAAGCCGAGTAAGCTAAAAACCAACATGAAGCAC-3Ј primer and the downstream 5Ј-GGTTGTGGTGACCGCGTGCTGCTTGATTG-3Ј primer. The PCR product was digested with NspI and separated on a 3% agarose gel. The Met 129 corresponds to three fragments of 75, 90, and 116 bp, whereas the Val 129 corresponds to two fragments of 116 and 165 bp. The MCF-7 cell endogenous PrP is heterozygous at codon 129. Endogenous PrP in human neurons was homozygous for Met, homozygous for Val, or heterozygous at codon 129.
Transfections
For cell death assays, human primary neurons were plated at a density of 3 ϫ 10 6 cells/ml onto poly-D-lysine-coated (20 g/ml; Sigma, Oakville, Ontario, Canada) plastic coverslips, and MCF-7 cells were plated at 2.5 ϫ 10 5 cells/ml onto glass coverslips in 24-well plates. The human neurons and MCF-7 cells on coverslips were transfected using the Helios Gene Gun system (Bio-Rad, Mississauga, Ontario, Canada) at a shooting pressure of 100 and 220 psi, respectively, according to the protocol of the manufacturer. Transfection cartridges were prepared with 0.033 mg of DNA, 4.2 mg of gold microcarrier beads in 0.1 ml of 1 M calcium chloride, and 0.1 ml of 0.05 M spermidine, as described previously . The microcarrier loading quantity of the transfection cartridges was 0.125 mg gold/shot, and the DNA loading ratio was 1 g DNA/shot. When cells were transfected with two constructs, a 1:3 ratio of pBud-EGFP-Bax/PrP or PrP mutants to pCep4␤-PrP, pCep4␤-CyPrP, pCep4␤-CyPrP mutant, pCep4␤-CyPrP GPI, or pCep4␤-CyPrP GPI mutant was used for the preparation of cartridges. For PrP expression, MCF-7 cells were plated in six-well plates at 1.5 ϫ 10 6 cells/ml or in 24-well plates at 2.5 ϫ 10 5 cells/ml and transfected with 4 or 0.8 g DNA, respectively, at a 3:1 ratio with pCep4␤-PrP:pCep4␤-EGFP, using Lipofectamine 2000 (Invitrogen) as described previously . The transfection efficiency was measured by counting EGFP-positive cells versus the total number of cells, using a Nikon (Mississauga, Ontario, Canada) eclipse TE2000-U microscope. The transfection efficiency in MCF-7 cells was constant at 20% for all mutants. N2a cells were plated in six-well plates at 0.8 ϫ 10 6 cells/ml and transfected with 4 g of pCep4␤-PrP or PrP mutants, pCep4␤-CyPrP or CyPrP mutants, or pCep4␤-CyPrP GPI or CyPrP GPI mutants using Lipofectamine 2000. The transfection efficiency was 70%.
Cell death measurement
Twenty hours after transfection, human neurons and MCF-7 cells were washed with PBS and fixed for 20 min at room temperature in 4% paraformaldehyde and 4% sucrose in PBS (150 mM NaCl, 2.7 mM KCl, 1.3 mM KH 2 PO 4 , and 8.1 mM Na 2 HPO 4 , pH 7.4), and the chromatin was stained 20 min with 1 g/ml Hoechst 33342 in PBS (Sigma). Cell death was measured by counting EGFP-positive cells displaying condensed chromatin versus the total number of EGFP-positive cells, using a Nikon eclipse TE2000-U microscope.
Detergent solubility assay
Forty-eight hours after transfection, MCF-7 cells in six-well plates were lysed with 0.2 ml of lysis buffer [150 mM NaCl, 2 mM EDTA, 0.5% Triton X-100 (v/v), 0.5% sodium deoxycholate (w/v), and 50 mM Tris-HCl, pH 7.5) for 20 min at 4°C. After a centrifugation at 11,500 ϫ g for 10 min at 4°C, the supernatant was collected and the detergent insoluble pellet was resuspended in 0.2 ml of Laemli's sample buffer [2% SDS (w/v), 5% ␤-mercaptoethanol (v/v), 10% glycerol (v/v), 0.01% bromophenol blue (w/v), and 62.5 mM Tris-HCl, pH 6.8]. The supernatant proteins were precipitated with 4 vol of ice-cold methanol overnight at Ϫ20°C and solubilized in the Laemli's sample buffer.
Western blot analyses
The proteins were separated in a 15% SDS-PAGE and transferred to polyvinylidene fluoride membranes, and PrP was detected with 1:2500 3F4 antibody (anti-PrP 109 -112 ) (Kascsak et al., 1987) . When indicated, 1:1000 polyclonal R155 antiserum ; produced in our laboratory) or 1:1000 6H4 (anti-PrP 144 -156 ; Prionics, Schlieren, Switzerland) and 1:1000 8H4 (anti-PrP 170 -180 ; Dr. Man-Sun Sy, Case Western Reserve University, Cleveland, OH) were used for PrP detection. Antibodies specific for ␤-actin (1:1000, Clone AC-15; Sigma), GFP (1:500, B-2; Santa Cruz Biotechnology, Santa Cruz, CA), cytosolic heat shock protein 70 (Hsp70) (1:1000; Stressgen Biotechnologies, Victoria, British Columbia, Canada), mitochondrial Hsp70 (1:1000, Clone JG1; Affinity BioReagents, Golden, CO), cytochrome c (1:1000, Clone 7H8.2C12; BD Pharmingen, Mississauga, Ontario, Canada), and Tau (1:1000, Clone T-5530: Sigma) were also used for Western blot analyses. Immunoreactivity was detected with 1:5000 anti-mouse or rabbit IgG conjugated to horseradish peroxidase secondary antibodies (Jackson ImmunoResearch, West Grove, PA) using chemiluminescence (GE Healthcare, Baie d'Urfe, Quebec, Canada).
Metabolic labeling of PrP
Forty-eight hours after transfection, MCF-7 cells were starved for 1 h in methionine-free DMEM and metabolically labeled for 3 h with 100 Ci/ml [ 35 S]methionine. Proteins were extracted and PrP was immunoprecipitated using the anti-PrP R155 antiserum, as described previously (Bounhar et al., 2001 ). The immune complexes were separated in a 15% SDS-PAGE and subjected to autoradiography.
PrP secretion in cell culture media
Forty-eight hours after transfection, MCF-7 cells in 24-well plates were washed once with serum-free DMEM, and fresh DMEM was added for 6 h. The cell culture media were then collected and centrifuged 5 min at 2000 ϫ g. The cells were washed with cold PBS and lysed with lysis buffer. All of the proteins from the supernatant and 20% of the cell lysate were precipitated with 4 vol of ice-cold methanol overnight at Ϫ20°C, resuspended in Laemli's sample buffer, and submitted to Western blotting against 3F4. The intensity of the protein bands were analyzed with a Personal densitometer SI (Molecular Dynamics, Sunnyvale, CA), and the ratio of secreted PrP over cellular PrP was calculated.
Phosphatidylinositol-phospholipase C treatment
Phosphatidylinositol-phospholipase C treatment of protein extracts. One hundred micrograms of protein extracts from transfected MCF-7 cells were treated with 0.0625 U of phosphatidylinositol-phospholipase C (PI-PLC) (Sigma) for 18 h at 37°C in the presence of complete protease inhibitor cocktail (Roche, Laval, Quebec, Canada) .
PI-PLC treatment of MCF-7 cells. Forty-eight hours after transfection, MCF-7 cells in 24-well plates were washed once with DMEM, and fresh DMEM containing 0.5 U/ml PI-PLC was added for 2 h. The cell culture media were collected and centrifuged 5 min at 2000 ϫ g. The cells were washed with cold PBS and lysed with lysis buffer. All of the proteins from the supernatant and 20% of the cell lysate were precipitated with 4 vol of ice-cold methanol overnight at Ϫ20°C, resuspended in Laemli's sample buffer, and submitted to Western blotting against 3F4.
Proteinase K, peptide-N-glycosidase F, and endoglycosidase H digestion
Resistance to proteinase K (PK) was assessed by incubating 100 g of proteins from MCF-7 cells extracted in lysis buffer for 20 min on ice with 2 g/ml PK. For peptide-N-glycosidase F (PNGase F) and endoglycosidase H (Endo H) digestions, 100 g of proteins from MCF-7 cells extracted in lysis buffer were adjusted to 0.5% SDS, boiled 10 min, and digested with 2 U of PNGase F (New England Biolabs, Pickering, Ontario, Canada) for 18 h at 37°C or with 25 U of Endo H (New England Biolabs) for 1 h at 37°C in the presence of protease inhibitors, as specified by the manufacturer. The reaction was terminated by the addition of Laemli's sample buffer and by boiling 2 min before submitting to Western blotting.
Subcellular fractionation
Subcellular fractionation was performed as described previously (Roucou et al., 2003) with some modifications. Twenty-four hours after transfection with pCep4␤-PrP or PrP mutant, N2a cells were treated with 0.25 M epoxomycin (BioMol, Plymouth Meeting, PA) and 5 g/ml brefeldin A (BFA) (Sigma) for 18 h. Cells were washed with cold PBS and homogenized with 30 strokes in a Dounce homogenizer in homogenization buffer [8% sucrose (w/v), 20 mM HCl-tricine, pH 7.8, and 1 mM EDTA]. The homogenate was centrifuged three times 5 min at 2000 ϫ g to eliminate unbroken cells and nuclei and then centrifuged at 100,000 ϫ g for 30 min. The supernatant and the pellet represent the cytosolic and membrane fractions, respectively. The pellet was resuspended in lysis buffer, and proteins from the supernatant were precipitated with 4 vol of icecold methanol overnight at Ϫ20°C. The intensity of the proteins obtained from Western blot analyses was analyzed with a Personal densitometer SI (Molecular Dynamics), and the ratio of cytosolic PrP over membrane PrP was calculated.
Statistical analysis
The statistical significance of the results was analyzed by ANOVA followed by Scheffé's post hoc analysis, using StatView (SAS Institute, Cary, NC). A p value of Ͻ0.05 was taken as a significant difference. The correlation coefficient and its statistical significance were determined using a Fisher's r to z transformation (StatView).
Results

All PrP mutants, except A117V and V203I, partially or completely lose anti-Bax function of PrP in MCF-7 cells
To investigate the function of familial human PrP mutants against Bax-mediated cell death, we chose the breast carcinoma MCF-7 cell line as described previously . MCF-7 cells do not express detectable endogenous levels of PrP and are transfected with relatively high efficiency, allowing us to study mutant PrP expression biochemically. The bigenic pBudCE4.1 vector was used for the study because we can express the Bax protein under the EF-1␣ promoter and PrP or PrP mutants under the CMV promoter. Furthermore, the CMV promoter is not highly expressed in MCF-7 cells and permits the study of the function of physiological levels of the mutant PrPs. MCF-7 cells are resistant to EGFP toxicity, but overexpression of Bax protein fused N-terminally with EGFP under the EF-1␣ promoter induces Bax-specific mediated cell death and allows visualization of the transfected cells . All PrP mutations in this study are associated with CJD, except for the PrP mutations A117V and Met 129 D178N, which are associated with GSS and FFI, respectively ( Fig. 1 A) . Each point mutation has been generated with a valine as well as with a methionine at codon 129. Eight of these PrP mutations are located at the C-terminal B or C ␣-helices of the protein. Only one mutation is between the B and C ␣-helices, two mutations are in the GPI signal peptide, and one is within the transmembrane domain.
Expression of EGFP-Bax alone in MCF-7 cells induces 61% cell death (Fig. 1 B) . When coexpressed with EGFP-Bax, Val 129 or Met 129 WT PrP decreases cell death by 50%. This is lower than observed against non-EGFP-tagged Bax, which is less toxic than EGFP-Bax, but it is still sufficient to analyze the anti-Bax function of PrP (Bounhar et al., 2001; Roucou et al., 2003 (Fig. 1C) . The cells look healthy and normal, indicating that the expression of the mutant PrPs is not inducing cell death. There is no correlation between PrP mutant cytotoxicity and loss of the anti-Bax function because the Val 129 E196K is slightly cytotoxic yet completely retains its anti-Bax function. Moreover, most of the PrP mutants that lose their anti-Bax function are not cytotoxic. These results show that the loss of anti-Bax function is not a direct consequence of mutant PrP-induced cytotoxicity.
The PrP M232R and PrP P238S mutations in the GPI anchor signal peptide allow cleavage of the C-terminal peptide and the addition of the GPI anchor Normally, the C-terminal signal peptide of PrP is cleaved from amino acids 232-253 for the addition of the GPI anchor (Englund, 1993) . Therefore, we investi- pCep4␤-PrP-, pCep4␤-PrPM232R-, pCep4␤-PrPP238S-, or pCep4␤-PrP⌬GPI-transfected MCF-7 cell protein extracts treated without (Ϫ) or with (ϩ) PI-PLC and deglycosylated with PNGase F. The arrow indicates a mobility shift as expected after removal of the GPI anchor. 
Change in the polarity or the charge of the amino acid in the PrP mutation are indicated, using ϩ if there is a change and Ϫ if there is no change. The location of the substituted amino acid in the secondary structure of PrP is provided. TM, Transmembrane domain.
gated whether the mutations M232R and P238S result in proper GPI posttranslational processing because both lose the anti-Bax function despite the mutations being in a part of the PrP that should be removed in the mature protein. PI-PLC followed by deglycosylation treatments of protein extracts induces a mobility shift of WT PrP (Fig. 1 D) as shown previously (Walmsley and Hooper, 2003) . As expected, the control PrP lacking the GPI signal sequence (⌬GPI) does not shift with the PI-PLC treatment. However, both the M232R and P238S PrP mutants undergo the same mobility shift as WT PrP, indicating that they have acquired the GPI anchor. Furthermore, the molecular weight of the deglycosylated M232R and P238S PrP mutants is identical to that of WT PrP, indicating that the signal peptides have been removed adequately. These results indicate that loss of function of these two PrP mutations is not attributable to the improper addition of the GPI anchor. (Endo et al., 1989) . Unfortunately, whereas EGFP expression is easily detected by Western blotting of pBud-EGFP/PrP-transfected MCF-7 cells, PrP is not (Fig. 2 A) . Only very low levels of PrP can be seen by immunoprecipitation of metabolically labeled pBud-EGFP/PrP-transfected MCF-7 cells (Fig.  2 B) . However, the level of PrP is easily detected in MCF-7-transfected cells with the episomal pCep4␤-PrP construct, which yields 50 -100 copies of the cDNA per cell (Groger et al., 1989) . To facilitate biochemical detection of the transfected mutant PrPs, we expressed the mutant PrPs under the CMV promoter of the pCep4␤ construct. PrP is absent in pCep4␤-transfected MCF-7 cells, confirming that the immunoreactive PrP proteins are from the exogenous expression of PrP mutants (Fig. 2C) . As a control, the ER-retained T183A PrP is almost completely sensitive to Endo H removal of high mannose sugars, as expected (Kiachopoulos et al., 2005) . Val/Met 129 WT PrP migrate mostly as mature glycosylated forms of PrP and are completely deglycosylated by PNGase F, resulting in 25 and 23 kDa proteins (Fig. 2 D) . The 25 kDa protein is consistent with the deglycosylated or immature form of PrP, whereas the 23 kDa likely represents a N-terminally cleaved product of deglycosylated PrP because the N-terminal-directed R155 PrP antibody does not recognize the 23 kDa protein (Fig. 2 E) . The immature high mannose glycosylated form of PrP represents only a small fraction of the total PrP, and this protein, migrating at ϳ30 kDa, shifts to 25 kDa during treatment with Endo H (Fig. 2 D) 
The levels of CyPrP generated by PrP mutants correlate with the anti-Bax function
CyPrP prevents Bax-mediated cell death in human neurons (Roucou et al., 2003) ; therefore, we investigated whether PrP mutations affect the levels of CyPrP (Fig.  3 ). pCep4␤-PrP or PrP mutanttransfected MCF-7 cells were treated with BFA and epoxomycin to inhibit proteasomal degradation and were submitted to subcellular fractionations into membrane and cytosolic fractions, as done previously (Roucou et al., 2003) . Unfortunately, BFA and epoxomycin treatment of MCF-7 cells results in the expression of endogenous human PrP (Fig. 3A) . Therefore, we switched to mouse N2a cells because the endogenous mouse PrP is not recognized by the 3F4 antibody. The presence of mitochondrial Hsp70 and cytochrome c only in the membranes and the presence of Tau protein mainly in the cytosol confirm the purity of the subcellular fractions (Fig. 3B) . In untreated cells, PrP is detected only in the membrane subcellular fraction. As shown previously, in the presence of epoxomycin and BFA, immature PrP is detected in the cytosol and membranes. The size of the CyPrP is consistent with retrotranslocated PrP lacking both the N-and C-terminal signal peptides because the deglycosylated CyPrP comigrates with recombinant human PrP (Fig. 3C) . In group I, the ratio of CyPrP over membrane PrP is equivalent or tends to be slightly higher than that of WT PrP (Fig. 3D) (Fig. 3E) . These results indicate that the reduction or loss of CyPrP from PrP mutants may be responsible for the deficit in anti-Bax function.
The inability of PrP mutants to generate normal levels of CyPrP is not accompanied with abnormal cell surface GPIanchored PrP levels
To examine whether there are other trafficking problems with the mutant PrPs, we looked at cell surface PrP. As observed previously (Winklhofer et al., 2003; Kiachopoulos et al., 2005) , PI-PLC treatment of the pCep4␤-PrP-transfected MCF-7 cells releases significant amounts of the WT or mutant PrPs (Fig. 4 A) . There is no consistent difference between group I, II, or III or between Val 129 and Met 129 PrP mutants, which indicates that the defect in making CyPrP is not accompanied by a problem with trafficking to the cell surface.
Similarly, secretion of PrP is not affected. In primary human neuron cultures, PrP is secreted into the media (Bounhar et al., 2001) as is WT or mutant PrPs from pCep4␤-transfected MCF-7 cells (Fig. 4 B) . Both the 25 kDa immature and 36 -40 kDa mature glycosylated forms of PrP are secreted. However, compared with 
Cotransfection of PrP mutants with wild-type or mutant CyPrP, but not with wild-type full-length PrP, rescues the loss of anti-Bax function in PrP mutants
To determine whether the decrease of CyPrP explains the loss of anti-Bax function in PrP mutants, we coexpressed CyPrP with all PrP mutants that have partially or completely lost the anti-Bax function. For this, we cotransfected MCF-7 cells with pBud-EGFP-Bax/PrP mutants and pCep4␤-CyPrP (Fig. 5) . CyPrP confers anti-Bax function to all pBud-EGFP-Bax/PrP mutanttransfected cells. To determine whether the PrP mutation also affect the anti-Bax function, we repeated the rescue experiment with pCep4␤-CyPrP mutants carrying the same mutation as that of the pBud-EGFP-Bax/PrP mutant. CyPrP mutant expression was confirmed (supplemental Fig. 3 , available at www.jneurosci.org as supplemental material). Two of the CyPrP mutants (M232R and P238S) were expressed with the GPI signal peptide because the mutations are present in this domain. Again, all mutant CyPrPs rescue the anti-Bax activity (Fig. 5) .
Finally, we attempted to rescue the loss of anti-Bax function in Together, these results indicate that the loss of CyPrP is responsible for the loss of anti-Bax function in PrP mutants. Furthermore, the inability of full-length WT PrP to rescue suggests that the PrP mutants have a dominant effect on the ability of wild-type PrP to retrotranslocate into the cytosol.
The loss of anti-Bax function in PrP mutants is more prominent in human neurons than in MCF-7 cells
We next investigated whether the mutant PrPs retain the anti-Bax function in primary cultures of human neurons. EGFPBax expression induces cell death within 24 h (Fig. 6 A) . As seen in MCF-7 cells, WT PrP inhibits EGFP-Bax-mediated cell death by 50%. (Table 2) . Furthermore, the position of the PrP mutations in the secondary structure of the protein does not correlate with the loss of anti-Bax function.
In contrast to the MCF-7 cells, human neurons were more susceptible to the mutant PrP expressions. The background level of cell death in nontransfected and EGFP-transfected human neurons is 15 Ϯ 3 and 16 Ϯ 3%, respectively. Therefore, EGFP is not toxic to these neurons. The Met 129 T188A, E200K, R208H, E211Q, V180I, E196K, M232R, and P238S and the Val 129 D178N, R208H, E211Q, M232R, and P238S mutants exhibit low but statistically significant cytotoxicity (Fig. 6 B) . However, as observed in MCF-7 cells, cytotoxicity does not correlate with the loss of the anti-Bax function.
Because it is not possible to transfect the human neurons with high efficiency, these studies are restricted to single-cell analyses. However, we did perform rescue experiments in three PrP mutants of the third group that completely lose the anti-Bax function. pCep4␤-CyPrP reduces cell death in pBud-EGFP-Bax/PrP V180I Met 129 -, E196K Met 129 -, and V210I Val 129 -transfected human neurons, but the difference does not reach statistical significance for pBud-EGFP-Bax/PrP V180I Met 129 (Fig. 6C) . As seen in MCF-7 cells, all CyPrP mutants rescue against the loss of 
Discussion
We show here that most of the familial PrP mutants exhibit a significant loss of the PrP anti-Bax function in human neurons and MCF-7 cells. The ability of mutants to protect against Baxmediated cell death is divided into three groups: (1) The loss of anti-Bax function in PrP mutants correlates entirely with a significant decrease in the production of CyPrP. CyPrP arises from incomplete translocation into the endoplasmic reticulum or retrotranslocation from the endoplasmic reticulum (Ma and Lindquist, 2001; Roucou et al., 2003; Rane et al., 2004) . Incomplete translocation results in a PrP that lacks the N-terminal signal peptide but retains the C-terminal GPI anchor signal peptide. Here, we find that the CyPrP does not contain the N-terminal or GPI signal peptides and thus is generated through retrotranslocation. The CyPrP has been shown to be cytotoxic in mouse neuroblastoma N2a cells and in cerebellar granular neurons, possibly through aberrant interaction with membrane lipids Lindquist, 2001, 2002; Wang et al., 2006) . The decrease in retrotranslocated CyPrP is unexpected because familial PrP mutants are associated with neuronal degeneration and cell death in human disease, a condition that could have been initiated by CyPrP cytotoxicity. However, CyPrP is not toxic and protects human neurons in primary cultures (Roucou et al., 2003) and MCF-7 cells (D. T. S. Lin and A. C. LeBlanc, unpublished observations) against Bax-mediated cell death. In addition, CyPrP is not toxic to a number of other human neuroblastoma cells (Roucou et al., 2003) . Here, we show that wild-type CyPrP rescues the loss of anti-Bax function in PrP mutants. Therefore, CyPrP is essential to PrP anti-Bax function. Furthermore, the mutant CyPrP also rescue against the loss of anti-Bax function in PrP mutants, indicating that the mutations in PrP do not alter the structural entity responsible for the antiBax function. Therefore, we conclude that these PrP mutants lose the ability to prevent Bax-mediated cell death because they cannot generate enough CyPrP.
Exactly how all of these PrP mutations alter retrotranslocation of PrP is not clear. The change in the charge, the polarity, or the position of the substituted amino acids in mutant PrPs do not correlate with the loss of anti-Bax function or the production of CyPrP. It is generally assumed that PrP mutations alter the conformation of the PrP. D178N, V180I, R208H, and V210I amino acid substitutions thermodynamically destabilize the PrP (Riek et al., 1998; Liemann and Glockshuber, 1999; Apetri et al., 2004) . However, not all PrP mutants are affected in this way. Moreover, mutant PrPs, such as D178N, possess misfolded protein characteristics (Lehmann and Harris, 1996) . Interestingly, even the M232R and P238S mutations, which are posttranslationally removed during GPI anchor addition, have reduced CyPrP levels. These results indicate that the C terminus of PrP regulates retrotranslocation of PrP before PrP is completely processed in the endoplasmic reticulum. Furthermore, the codon 129 polymorphism regulates retro-translocation because in group II, Val 129 containing mutants have normal levels of CyPrP and retain their anti-Bax function, whereas Met 129 containing mutants have reduced CyPrP levels and partially or completely lose the anti-Bax function. Relative to Val 129 , the Met 129 increases the ability of PrP to fold with a higher ␤-sheet content and to oligomerize (Tahiri-Alaoui et al., 2004) . Therefore, it is likely that codon 129 and familial mutations slightly alter the conformation of PrP, thus resulting in altered posttranslational trafficking.
We also find that the mutant PrPs do not accumulate into the endoplasmic reticulum, are normally glycosylated, and accumulate at the cell surface as GPI-anchored proteins. These results suggest that the mutant PrPs escape the normal regulatory checkpoint for misfolded proteins, which constitutes 10% of newly synthesized WT PrP (Yedidia et al., 2001) . Because many PrP mutants resist limited PK digestion, the mutants are likely misfolded. Cell surface PrP has been shown to induce several beneficial signaling transduction pathways (for review, see Roucou et al., 2004; . The accumulation of these misfolded proteins could be detrimental to the normal function of PrP at the cell surface of the neurons. (Wadsworth et al., 2004) . Our results in human neurons showing abrogation of anti-Bax function in all Met 129 PrP mutants are also consistent with the observations that individuals homozygous for methionine are more susceptible to develop a prion disease (Kovacs et al., 2005) . Interestingly, all CJD human familial mutations encode a Met 129 on the mutant allele. In addition, D178N and E200K mutations are also found with a Val 129 mutant allele (Hoque et al., 1996; Windl et al., 1999; Peoc'h et al., 2000; Kovacs et al., 2005) . Codon 129 strongly regulates the phenotypic manifestation of CJD (Val 129 ) and FFI (Met 129 ) associated with the D178N mutation and the prion disease linked to the E200K mutation (Goldfarb et al., 1992; Hainfellner et al., 1999) . Moreover, codon 129 polymorphism affects the type of pathological PrP in genetic prion diseases and, in some cases, the age of onset (Baker et al., 1991; Monari et al., 1994; Gambetti et al., 2003; Kovacs et al., 2005) . Our observations show the additional influence of codon 129 polymorphism on the retrotranslocation and anti-Bax function of PrP mutants.
We confirm that the loss of anti-Bax function also occurs in human neurons. However, the loss is more prominent in human neurons than in MCF-7 cells. The Met/Val 129 A117V and V203I group I mutations that retain protection against Bax in MCF-7 cells shift to group II in human neurons. Moreover, group II mutations Val 129 V180I, E196K, and R208H that retain function in MCF-7 cells shift to group III in human neurons. One possible explanation for this difference is that the mutant PrPs are more cytotoxic to human neurons than MCF-7 cells. Unfortunately, it is impossible to study in these human neurons the level of CyPrP to determine whether it is lower in all of the mutants because primary cultures of human neurons are highly resistant to infections or transfections and ballistic transfection into the human neurons occurs at very low transfection efficiency and limits us to single-cell analyses. However, we show by cotransfection experiments that CyPrP and CyPrP mutants, but not WT full-length PrP, also rescue the anti-Bax function of PrP mutants in human neurons. These results indicate that CyPrP deficits are also responsible for the loss of anti-Bax function in human neurons.
Neuronal apoptosis is observed in FFI and familial CJD (Gray et al., 1999; Ferrer, 2002) . Because clinical symptoms are manifested during aging in familial cases, it is possible that the loss of anti-Bax prion function contributes to age-dependent Baxmediated apoptosis. Several age-dependent insults, such as oxidative stress and endoplasmic reticulum stress, activate Bax (Savory et al., 1999; Keller et al., 2002; Phaneuf and Leeuwenburgh, 2002) . Interestingly, the universal anti-Bax inhibitor protein Bcl-2 decreases in the aging CNS (Merry et al., 1994) . Because Bcl-2 has wide-ranging effects on many proapoptotic proteins, it is possible that PrP, which is quite specific against Bax , replaces the broader Bcl-2 protein for a more focused effect against Bax-mediated cell death in the aging CNS. Therefore, it is possible that the loss of anti-Bax function in PrP mutants contributes to the loss of neurons in prion diseases.
In summary, we find that PrP mutants associated with familial prion diseases lose their anti-Bax function and that this loss of function is attributable to a deficit in generating CyPrP. The loss of the anti-Bax function in mutant PrPs may result in a higher susceptibility of neurons to agedependent Bax-mediated neuronal cell death in familial prion diseases. In addition, these results suggest that the mutant PrPs escape the retrotranslocation pathway normally responsible for removing misfolded protein. In these conditions, the accumulation of misfolded PrP could adversely affect neuronal function. Change in the polarity or the charge of the amino acid by PrP mutation are indicated, using ϩ if there is a change and Ϫ if there is no change. The location of the substituted amino acid in the secondary structure of PrP is provided. TM, Transmembrane domain.
